IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024

An Analysis and Review of Pharmaceutical Product Recalls

Harish Tulsidutt Bhatt[1] and Dr. Sanjay Kisanrao Bais[2]
Research Scholar, Department of Pharmacy[1]
Research Guide, Department of Pharmacy[2]
Sunrise University, Alwar, Rajasthan, India

Abstract: *Recalls of recalled medications are essential to maintaining the quality system since they take defective goods off the market, which is the pharmaceutical industry's main objective in offering the public high-quality medical products. The industry is seeing an alarming rise in concerns about recalls of pharmaceutical products as a result of increased inspection rates, modernization, and the entry of the internet world. Because of this, public health and regulatory agencies are concentrating on tightening laws to avoid future recalls of defective pharmaceutical items. This article will provide an overview of recall procedures, their consequences on the pharmaceutical industry, and the many steps taken to reduce the frequency of pharmaceutical recalls.*

Keywords: Manufacturing defects, Contamination.

I. INTRODUCTION

Quality, safety, and effectiveness are regulatory authorities' top priorities for authorizing new pharmaceuticals. The agency and manufacturer components of the pharmacovigilance research are then assessed for medication side effects, and if any concern about product quality is raised, it puts human health at risk and is revoked. Take a hazardous or defective product off the market by recalling it. The manufacturer may initiate a recall voluntarily or be prompted by regulatory organizations. Regulatory entities enforce product standards and regulations to safeguard human and animal health. They safeguard and check commodities and make it permissible for firms to recall illegal drug products.1 infractions such stock rotation and upkeep that conventional regulators would consider illegal.2. A producer may recall a batch or lot of marketed products; medication recalls are handled at wholesaler, retailer, and consumer levels depending on the risk. Not all recalls are severe.

Due to their rapid development in recent years, drug recalls have caused worry and many problems. Why are medications being recalled, what are the consequences, how will the recall affect the pharmaceutical business, how will it affect public health, how much money the company will lose, and most importantly, what should be done?

A manufacturer may initiate a recall in response to a formal request or order from a regulatory body, state authority, or regulatory agency. Pharmaceutical recalls differ from stock recoveries and market withdrawals. Due to little New Delhi, India's Delhi Pharmaceutical Sciences and Research University, a corporation may remove or correct a product.

Classification of recall

The recall procedure aims to improve consumer protection and the health system to assure success. Finding the reason of a product recall is crucial. Three risk-based groupings of recalls exist in different countries. Class 1 is most likely to cause major harm, whereas Class 3 is least likely. Recalls are meant to raise awareness, not based on these categorization. A few categorizations are provided in Table 1.

Most governments characterize recalls as public health and quality control measures. The decentralized European Medicines Agency (EMA) specifies recall in Article 44 of Directive 2001/82/EC. The US FDA defines recall in 21 CFR PART 7 sec.41.5. Par. 27 and 28 of schedule M (Good Manufacturing Practices) of the Drugs and Cosmetics Act 1940 and Rules 1945 specify product recall, complaints, and adverse reactions.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024

Process of pharmaceutical product recall

When a complaint is received about a regulatory infringement that might result in slight to major harm to public health, a pharmaceutical recall procedure will be initiated. FORM-483 is typically included in complaints. The FDA investigator of the office of regulatory affairs documents the results of a site visit.Six The USFDA creates establishment inspection reports to make decisions on what to do; this process is known as inspectional observation. The USFDA will issue a warning notice if the company or manufacturer does not respond to the observations within a period of fifteen days.7.

Inspections of surveillance facilities focus on current good manufacturing practices in order to preserve quality. They may be divided into three groups.

OAI – Official action indicated

1.VAI – Volunteer action indicated

2. NAI – No action indicated

OAI is an inspection classification meaning that regulatory action should be suggested. This includes voluntary drug product recalls, warning letters, import warnings, injunctions, and the regulatory authorities seizing products that violate the law. Despite the fact that an adverse observation was found by the authority's volunteer action program (VAI), no legal or regulatory action was planned at that time.8

Table 1. Classification of recall with selected examples.

Class 1

Descriptions A circumstance in which there is a fair risk that using a violative substance could result in severehealth problems in the public and even death.

Examples Wrong products with prominent medical outcomes.

Severe medical effects due to chemical contamination.

Sterile and ophthalmic preparations with microbial contamination. The wrong active ingredient in multiple components products should be a reason for serious medical issues.

Class 2

Descriptions A situation in which the use of a contraceptive drug can trigger temporary health problems inpublic that are medically reversible or have a low risk of serious health consequences.

Examples Inappropriate labeling

False information in leaflets and medical literature

Non-sterile and non-ophthalmic with microbial contamination

Non-compliance with the specification, which is related to assay, stability, testing, or weightresulting in medical consequences.

Class 3

Descriptions A condition in which the use of a prohibited substance does not result in significant health consequences.[3]

Examples ● Faulty packaging, missing of a product number, and batch number.

Contamination with no medical consequences products such as

Microbial spoilage

Dirt Particulate matter

● Faulty closures not associated with any medical consequence

Recall initiation: voluntary and involuntary recalls (after a complaint or probable negative repercussions) should follow these principles.

if the action is a recall depends on its scope, strategy, and if it impacts consumers, merchants, or wholesalers. FDA evaluates recall actions by determining whether they are recalls under 21 CFR 7.3(g). FDA evaluates business or manufacturer recall plan information.

Notification and disclosure: The FDA evaluates the company's recall strategy and suggests changes including a public statement and classification notification. The FDA notifies state agencies and overseas organizations and posts recall information on several websites.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024

Monitor and audit the recall: The FDA uses a recall audit technique to ensure recall success.
USFDA terminates recalls. It may cease when all harmful pharmaceuticals are removed off the market. Level 1 terminations need regulatory body prior consent, however level 2 and 3 terminations do not.9.

Analysis of pharmaceutical product recall

One of the biggest industries in the world, the pharmaceutical sector generates $1.3 trillion in sales worldwide, with India accounting for almost $20.1 billion of that total. The economy and the health sector will be impacted by any unfavorable news from the sector. Recalling pharmaceutical products is something every company should avoid doing since it tarnishes its brand with consumers and authorities. It costs manufacturers and regulators money and effort since each of the three classes has different recall methods and schedules.10 According to the Indian regulatory body, the Central Drugs Standard Control Organization (CDSCO) period for class 1 is 24 to 72 hours, class 2 is 10 days, and class 3 is 30 days.

In recent years, major finished products used to treat large populations for common diseases like diabetes, hypertension, and gastric reflux have been recalled due to undesired impurities above regulatory guidelines, raising patient safety concerns. Every year, about 5000 drugs, biologics, medical devices, cosmetics, etc. are recalled. About 25% are drugs. USFDA enforcement data shows that class 2 has 5250 recall occurrences since January 1, 2016, followed by class 1 with 923 and class 3 with 741. DRUGS recalls have happened in all three classifications 6914 times. To understand recall, we must focus on its causes and industry effects. A table highlights major recall reasons. Class 1 recalls were caused by microbial contamination, class 2 by lack of sterility assurance, and class 3 by erroneous labeling. Table 2 lists common drug product recall causes: sterility issues, improper labeling, particulate matter, marketing without an NDA or ANDA, subpotent products, failed impurities, inadequate processing control, failed dissolution specification, microbial contaminations, cross-contaminations, and subpotent products11.

Presence of particulate matter –

Pharmaceutical parentral formulations are very susceptible to particulate matter, with almost all parenterals including some amount of particle matter. In order to counter this, all regulatory bodies released rules on particulate matter, and authorized organizations let a specific level of particulate matter to exist as long as it stays within the established bounds.19 Manufacturers may abide by the USFDA's particle matter standards for both large- and small-volume parenterals to prevent recalls and other quality issues that can result in lung sacring, blood vessel blockage, and serious allergic responses. Parenteral limits are shown in Table 3.

Table 2. Parameters for parenteral.Parentral

Large volume parentral	
Particles per ml of 10 lm	Not more than 50 particles.
Particles per ml of 25 lm	Not more than 5 particles.
Small volume parenteral	
Particles per ml of 10 lm	Not more than 10,000 particles per container in implicit spherical diameter.
Particles per ml of 25 lm	Not more than 1000 particles per container in implicit spherical diameter.[20]

Building constructions, testing techniques, and sterile product preparation processes were all covered by Industries 21 CFR Part 211 Subpart F (sec. 211.113).22

Marketed without an Approved NDA/ANDA –

No matter if the corporation has an ANDA or NDA, relevant regulatory agencies must approve every product sold under a class 1 recall according to risk categorization. These agencies may authorize applicants after assessing safety, quality, and effectiveness evidence. The USFDA states that all manufacturers must follow industry regulations regarding unapproved drugs because doing otherwise jeopardizes the agencies' approval processes, damages NDA patent holders' reputation and confidence, and allows the FDA to seize or injunct the sale of unapproved products within a year (the grace period) of market authorization.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024

CGMP Deviations –

Class 2 goods were mostly recalled by the USFDA due to cGMP or sterility concerns. Current good manufacturing practices have resulted in the second-highest number of recalls in recent years, behind sterility assurance, and GMP breaches have drawn attention to nitrosamines (carcinogenic chemicals). Figure 1 displays the primary causes of recall.

Nine nitrosamines were identified by regulatory businesses as mutagens, whereas NDMA and NDEA were mostly found in sartans, H-2 blockers, and now metformin.24 Some scientists speculate that defective items might be the result of B2 carcinogen, NDMA, which is found in soil and water and can cause water poisoning. Market authorization holders are required by regulatory bodies like the European Medicine Agency (EMA) to provide self-evaluation review reports on their goods, whether they are chemicals or biologics, in an effort to decrease the frequency of drug product recalls caused by nitrosamine impurities.25

Microbial contamination –

Water is the primary source of contamination in both sterile and non-sterile items. However, since even a little infraction may have a major effect on public health, sterile products are more concerned about water contamination than non-sterile products. After a product's lack of sterility assurance, microbial contamination in sterile pharmaceutical items is the second most frequent cause of recalls. Among the most prevalent bacteria found in pharmaceutical products are Aspergillus species, B. cepacia, C. albicans, Bacillus species, and Klebsiella species. Recommendations for evaluating the microbial load at various dosage forms have been provided by the USFDA and other regulatory organizations due to the seriousness of the condition and its involvement in producing a broad variety of ailments, from slight discomfort to death.26

Labeling –

Pharmaceutical product labeling aims to make the quality system transparent and gives patients clarity by including all necessary information, such as the dosage form, ingredients and their quantities, manufacturing and expiration dates, and instructions for use. Since many patients follow the labeling instructions before using the product, any error in the labeling of drug products can have serious consequences and compromise the integrity of the system. In the last five years, according to our data analysis of USFDA recalls, label errors accounted for approximately 7% of all recalls. Various regulatory agencies from different countries have therefore issued specific guidelines for labeling compliance, which manufacturers must follow in order to maintain the quality system. For instance, endopharmacical recalled Robaxin 750 mg tablets because the recommended dosage was incorrectly labeled as two to four tablets four times per day instead of two tables three times per day.27

Recall data (enforcement report) from the FDA indicates that the six causes listed above account for up to 90% of all recalls. Approximately 60% of recalls are attributable to CGMP deviations and a lack of sterility, with the remaining 40% of recalls occurring during the previous five years for other reasons. The overall number of recalls increased between 2016 and 2019, particularly class 2 recalls. In contrast, in 2020, there was a decrease in recalls, which can be partially attributed to nationwide lockdowns in several nations and a reduction in regulatory agency inspections due to the COVID-19 pandemic. The class 1 recall rate has been erratic over the last five years, whereas the class 3 recall rate has been declining since 2017. This trend may be related to the company's primary emphasis on preventative measures by enhancing their quality system and management, as shown in Figure 2.

Impact of recall

Recall implications are analyzed for user convenience because pharmaceutical product recalls, whether mandated or voluntary, have the potential to negatively impact the manufacturer's exposure to product liability in a variety of ways. Recalls of pharmaceutical products may affect a wide range of aspects of the pharmaceutical industry, including supply chains, distribution, public health, market shares, corporate science reputation, supply chain, and the loss of patent protection for certain products. As a result, it is imperative that

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024



Figure 1. Number of different classes of recall that happened in the last five fiscal years.

Be informed about your goods to reduce the likelihood that you will be considered as a candidate.
Recalls of pharmaceutical products may have an impact on the following areas.

Economical loss –

Drug development is laborious and time-consuming. From discovery to licensure, medication development costs millions and takes 10–15 years. If a medicine is recalled after that, the corporation loses market share and money. Due to Lupin's recall of metformin extended-release for type 2 diabetes, Fortamet and Glumetza sold $25 million and $15 million to our FY21 and FY22. Although considerable, analysts estimate that its US sales in FY20 averaged $25–40 million, or 3%–5% of its overall revenue.28

Pharmaceutical company status Drug product recalls hurt a company's market share, financial capital, and brand and corporate image. Because the corporation cannot maintain a high quality standard, has been engaged in fraud, generated fake clinical studies, or caused patient safety issues, recalls may damage consumer impressions. A product recall also lowers investor trust.

Corporate science –

The approval of medications in each nation is the responsibility of the regulatory bodies in that nation. A drug product may be recalled from the market after a few years of use if regulatory authorities approve it primarily on the basis of data provided by the pharmaceutical company rather than doing safety research on the product.30 For instance, VALDECOXIB was approved in 2005.

Supply chain –

The supply chain is essential to market recalls for pharmaceuticals. The promptness and efficacy of a recall might impact a brand's capacity to regain revenue, clientele, and reputation. Compliance and recalls are major concerns for manufacturers and pharmaceutical companies. To support medication restoration, the USFDA enacted the medication Supply Chain Security Act for pharmaceutical companies and the Consumer Protection Act for consumers. The manufacturer's current responsibilities are challenging, but they include removing all defective products from the market, setting up an electronic tracking system with barcodes, RFID technology, color-shifting ink, 3D holograms, and other techniques, and documenting a successful product restoration for future inspection and analysis by an authority.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024

Distribution and development -
Pharmaceutical companies used manufacturing networks, third-party involvement, loan licensing, and B2B alliances to grow. The main difficulty is that it might be difficult to determine the source of a product fault and assign responsibility. various manufacturers and suppliers provide various ingredients for completed goods, making it difficult to discover flaws. Due to absence of standards or disdain for regional pharmaceutical distribution legislation, pharmaceutical distribution relies on wholesalers and retailers during recalls. This is another important recall impact.

Steps to reduce the recall
Recalls of drugs are serious incidents that, if not managed properly, might harm the general population and increase the risk of a public health emergency. Recalls are a hardship for pharmaceutical companies because they need to have positive relationships with regulatory agencies and uphold their brand. Eliminating the cause is one of the best strategies to reduce recalls rather than using rectification processes, since recalls have increased dramatically in recent years due to quality or negligence problems that could have been addressed.

Compliance with regulatory agencies –
To minimize recalls and quality issues, companies must follow laws, rules, regulations, and process-specific requirements. Companies or manufacturers must identify the precise rules provided by competent authorities, write papers according to the standards, and follow the same for changes to fulfill these requirements and laws.

Follow CGMP(current good manufacturingpractices) –
In order to prevent faults and their consequences, manufacturers and firms must adhere to WHO CGMP and 21 CFR part 210 & 211. Recalls resulting from poor manufacturing procedures have become more frequent in recent years and are reason for considerable worry (recall due to nitrosamine impurity in regularly used medications). In order to assist in making informed judgments that would lower recalls, these papers also provide statistics and reports.

Automation system-
Errors in labelling and packaging were responsible for around half of recalls. Typical errors included misprints, incorrect text, graphics, and barcodes, as well as the omission of crucial information. Pharmaceutical firms recognize the importance of preventing mistakes and use automation technology to achieve this goal. Automation provides a thorough quality system that helps companies find mistakes at every level of the product manufacturing process. For instance, minute glass pieces in packaging might cause product recalls and affect the quality of the product. Automation technologies also protect brand integrity, change customer impression, and help discover human mistake. Several producers enhanced their vision system to include optical character recognition (OCR) in order to guarantee that the goods meet all necessary criteria.

Total quality management –
Total quality management is a systemic approach adopted by pharmaceutical companies for long-term success and customer satisfaction. All members work together to improve services and products, and recalls due to human errors, system errors, and complaint failures can be prevented. It includes four steps: quality inspections, quality control, quality management, and quality assurance, which helps avoid medication recalls and quality problems in pharmaceutical products.36 In 2020, ETQ found that 96% of industries had a product recall in the last five years and 86% of firms said quality management systems helped control and recover from recalls.

System integrity –
Most time-specific batches of goods are recalled instead of the whole product, and the chain must be maintained to protect and track data. Manufacturers must follow packaging criteria to monitor

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024

items from the lot or pool throughout the supply chain to avoid these regulatory authorities. Identifying a single lot or product from a pool of items simplifies recall management. It reduces product waste, labor expenses, and safeguards patients by monitoring illegal materials.

Setting corrective actions and preventive actions-

Throughout the course of a product's life cycle, the pharmaceutical industry employs the CAPA quality management system to identify and resolve issues at their core. According to ICH Q10, its applications include product discounting, commercial manufacturing, knowledge transfer, and pharmaceutical development.39 Analysis of USFDA recall data conducted in the past shows that typical causes of recalls include microbiological contamination, GMP violations, and inadequate quality control. In the industrial sector, CAPA is essential for managing and reducing recall incidents Forty

II. CONCLUSION

Patients worry about using defective or recalled drug products in the future, but recalls are mostly done to improve the quality system and protect the public from violative products, whether requested voluntarily or by regulatory agencies. The frequency of recall events in the pharmaceutical business grows as innovation and technology develop, the industry becomes more internationally linked, and regulatory agencies impose stronger restrictions. Because of this, researchers have to identify remember occurrences, start creating preventive techniques to decrease their impacts, and build a mechanism to manage them by boosting workplace culture and delivering staff training. Recalls may be devastating to the industry, influencing everything from a company's financial line to its position in the marketplace. However, recalls may be controlled or the chance of an unavoidable recall lowered by carrying out recalls appropriately and adopting a variety of preventive measures.

REFERENCES

[1]. Gad SC and Vales. T. Recalls, drugs and consumer products. Encyclopedia of toXicology. 3rd ed., vol. 4. Amsterdam: Elsevier, 2014.
[2]. Recalls, Corrections and Removals Medical device
[3]. recalls and corrections and removals. Available at: https://www.fda.gov/medical-devices/postmarket-requirements-devices/recalls-corrections-and-removals- devices.
[4]. Food T. U. S. differences among FDA class I, II, and III
[5]. recalls get the compensation you deserve. 2020; 1–3.
[6]. EXamples of different classes of recall action 27. 2020; 1–4.
[7]. Food and Drug Administration (FDA). CFR – Code of Federal Regulations Title 21 The information on this page is current as of April 1 2016. 2017; 721: 1–10.
[8]. LuXminarayan L, Neha S, Amit V, et al. Asian journal of pharmaceutical research and development. *Asian JPharm Res Dev* 2017; 5: 1–8.
[9]. Article R. Findings and regulatory inspections ofUSFDA form 483. 2020; 61: 83–87.
[10]. Food T. Inspections database frequently asked ques- tions. 2021; 1–2.
[11]. FDA. Regulatory procedures manual – 4-1 – WARNING LETTERS. 2012; 1–115.
[12]. Venkatesh MP, Bigoniya D and Pramod T. Pharmaceutical product recall procedures in India, South Africa and China. Int J Pharm Sci Rev Res 2017; 46: 98–104.
[13]. Yang M, Byrn SR and Clase KL. An analytic investiga- tion of the drug formulation-based recalls in the USA: see more beyond the literal. AAPS PharmSciTech 2020;21: 1–10.
[14]. Announcement, C. Fresenius Kabi issues voluntary nationwide recall of ketorolac tromethamine injection, USP due to the presence of particulate matter. 2021; 2019–2022.
[15]. Announcement, C. Innoveix Pharmaceuticals, Inc. issues voluntary recall of all sterile compounded drug products due to a lack of sterility assurance. 2021; 3–5.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024

[16]. Announcement, C. A & H Focal Inc. issues nationwide recall of 21 products marketed as dietary supplements & one cosmetic product due to the possible presence of undeclared erectile dysfunction ingredients. 2021; 2–4.

[17]. Adamson RH and Chabner BA. The finding of N-nitro- sodimethylamine in common medicines. Oncologist2020; 25: 460–462.

[18]. Tavares M, Kozak M, Balola A, et al. Burkholderia cepacia complex bacteria: a feared contamination risk in water-based pharmaceutical products. Clin. Microbiol. Rev 2020; 33: 1–25.

[19]. Acella Pharmaceuticals, LLC issues voluntary nation- wide recall of two lots of NP Thyroid® , thyroid tablets, USP due to sub potency. FDA, www.fda.gov/safety/ recalls-market-withdrawals-safety-alerts/acella-pharma ceuticals-llc-issues-voluntary-nationwide-recall-two- lots-np-thyroidr-thyroid-tablets (accessed 8 July 2021).

[20]. Altaire Pharmaceuticals, Inc. issues voluntary recall of multiple ophthalmic products manufactured and dis- tributed as Altaire labeled products. FDA, www.fda. gov/safety/recalls-market-withdrawals-safety-alerts/ altaire-pharmaceuticals-inc-issues-voluntary-recall-mul tiple-ophthalmic-products-manufactured-and (accessed8 July 2021).

[21]. Tawde SA. Particulate matter in injectables: main cause for recalls. J Pharmacovigil 2015; 3: 1–2.

[22]. Desmukh MT, Salunkhe RS, Deshmukh VT and Shete RV. Quality control test's for parenteral preparations: a review. J Curr Pharm Res 2015; 5: 1425–1430.

[23]. Kolluru LP. Sterility assurance of parenteral products – major deficiency for recall. 2017; 5: 4–5.

[24]. FDA. Sterile drug products current good manufacturing practice guidance for industry. Filtration 2004; 1–63.

[25]. New M and Without D. Guidance for FDA staff and industry marketed unapproved drugs – compliance policy guide guidance for FDA staff and industry mar- keted unapproved drugs – compliance policy guide. *Fed Regist* 2006; 1–15.

[26]. Shaik KM, Sarmah B, Wadekar GS, et al. Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techni- ques. Epub ahead of print. *Crit Rev Anal Chem* 2020; 1–19.

[27]. European Medicines Regulatory Network approach for the implementation of the CHMP Opinion pursuant to Article 5 (3) of Regulation (EC) No 726/2004 for nitro- samine impurities in human medicines. 2021; 5.

[28]. Mugoyela V, Mugoyela V and Mwambete KD. Microbial contamination of nonsterile pharmaceuticals in public hospital settings. Ther Clin Risk Manag 2010; 443–448.

[29]. Endo pharmaceuticals issues voluntary nationwide recall for two lots of Robaxin® 750mg tablets 100 count bottle packs due to incorrect daily dosing infor- mation on label. FDA, www.fda.gov/safety/recalls- market-withdrawals-safety-alerts/endo-pharmaceuti

[30]. cals-issues-voluntary-nationwide-recall-two-lots-robax inr-750mg-tablets-100-count (accessed 8 July 2021).

[31]. Recall of metformin formulations in the US by Lupin may hit profitability, www.livemint.com/market/mark- to-market/lupin-s-recall-of-metformin-formulations-in- the-us-to-hit-profitability-in-q2-11594274825091.html (accessed 8 July 2021).

[32]. Quanhong L and Xin Z. Corporate product recall and its influence on corporate performance. 2015; 241–246.

[33]. A list of the non-selective NSAIDs is available on http:// www.fda.gov/cder/drug/infopage/coX2/default.htm. The degree of COX-2 selectivity for any given drug has not been definitively established, and there is considerable overlap in. 2005; 1–19.

[34]. Mg M, Tm PK and Mp V. Biological and chemical sciences regulation of reverse logistics of pharmaceutical products in United States. *Res J Pharm* 8: 2017. 315–320.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, February 2024

[35]. Shewale SD, Chavan M and Parekh SS. Pharmaceutical product recall: lesson learned. Int Pharm Ind 2014; 6(1), 1–23.

[36]. What is regulatory compliance? https://searchcompli ance.techtarget.com/definition/regulatory-compliance (accessed 8 July 2021).

[37]. Parker BR and Lahr JG. Pharmaceutical recalls: Strategies for minimizing the damage. Drug Information J 1999; 33: 541–556.

[38]. Automation for preventing pharmaceutical recalls – pharmaceutical processing world, www.pharmaceutical processingworld.com/automation-for-preventing-ph armaceutical-recalls/ (accessed 8 July 2021).

[39]. Sweis R, Ismaeil A, Obeidat B, et al. Reviewing the lit- erature on total quality management and organizational performance. J Bus Manag 2019; 7: 192–215.

[40]. 4 stats that show how quality management impacts product recalls – ETQ, www.etq.com/blog/4-stats-that-show-how-quality-management-impacts-product- recalls-2/ (accessed 8 July 2021).

[41]. Ebel T, et al. *Strength in unity: the promise of global stand- ards in healthacre*. USA: McKinsey Co., 2012, pp.1–75.

[42]. Services H. Room 2201 Silver Spring. 2009; 51:20852–21448.

[43]. Wu A, et al. Enhanced Reader.pdf. Nature 2020; 388:1–14.